Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aerie Pharmaceuticals (NQ: AERI )

17.90 USD +0.31 (+1.76%)
Streaming Delayed Price Updated: 11:14 AM EDT, May 13, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 78,462
Open 17.69
Bid (Size) 17.88 (3)
Ask (Size) 17.93 (1)
Prev. Close 17.59
Today's Range 17.69 - 18.32
52wk Range 9.010 - 21.30
Shares Outstanding 46,893,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients... 
From Business Wire News Releases
Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients... 
From Business Wire News Releases

Performance

YTD
+36.43%
+36.43%
1 Month
-2.77%
-2.77%
3 Month
+5.05%
+5.05%
6 Month
+37.16%
+37.16%
1 Year
+14.60%
+14.60%

More News

Read More
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
From Business Wire News Releases
Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
From Business Wire News Releases
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Business Wire News Releases
Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain
From Business Wire News Releases
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
From Business Wire News Releases
Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
From Business Wire News Releases
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase
From Business Wire News Releases
Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference
From Business Wire News Releases
Notable Friday Option Activity: AVID, TMUS, AERI
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.